Rexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the appointment of Peter Brandt and Richard Kivel to the company’s board of directors.

“Peter and Richard are driving forces for innovation in the life science industry, and both are exceptional leaders who have accelerated corporate growth throughout their careers,” said Chang Ahn, Chief Executive Officer, Rexahn Pharmaceuticals. “Their proven expertise in commercializing biomedical innovations, and extensive financial and operational experience are significant assets to Rexahn as we continue to develop best in class CNS and cancer therapeutics and collaborate with pharmaceutical companies around the world.”

“I am honored to join Rexahn’s board. The company is at the forefront of developing innovative therapies for CNS disorders and cancer,” said Mr. Brandt. “I look forward to contributing to Rexahn’s evolution towards becoming a leading biopharmaceutical company.”

Mr. Kivel added, “This is an exciting time for Rexahn,particularly with three promising drugs in mid-stage development, and I look forward to helping the company capitalize on its impressive portfolio of potential new drugs.”

Peter Brandt was most recently President and Chief Executive Officer of Noven Pharmaceuticals, a specialty pharmaceutical company based in Miami, Florida. Prior to leading Noven, Brandt spent 28 years at Pfizer, the world’s largest pharmaceutical company. He served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he helped deliver revenue and earnings growth while engineering major change within Pfizer’s U.S. pharmaceuticals organization. Prior to running the U.S. operations, he led the Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also oversaw the operations of Pfizer’s care management subsidiary, Pfizer Healthcare Solutions.

Richard Kivel is a serial entrepreneur and seasoned life science and technology executive and presently serves as Chairman of Rhapsody Biologics, a biotech company focused in the field of vaccine development, with offices in the US and Singapore. Previously, Kivel served as CEO of TheraGenetics, a UK-based genetic diagnostics company focusing on the development and commercialization of pharmacogenetic diagnostic tests to guide and improve the treatment of Central Nervous System (CNS) disorders.